|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters.
|
16061909 |
2005 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.
|
21625079 |
2011 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Subset analysis of cases that had undergone radical prostatectomy revealed an association between rs351855 and prostate cancer risk.
|
18762813 |
2009 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer.
|
28445975 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.
|
21349172 |
2011 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men.
|
19918264 |
2010 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Three common polymorphisms (rs1966265, rs2011077, and rs351855) of FGFR4 were genotyped from 346 patients with prostate cancer by using the Sequenom MassARRAY system.
|
27640814 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population.
|
18756523 |
2008 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, the FGFR4 functional polymorphism G388R has been associated with poor outcome in several human malignancies.
|
20660043 |
2010 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results provide evidence of a role for the FGFR4 Gly388Arg polymorphism in modulating patients' outcome in different types of cancer, thus offering to clinicians a new marker to predict predisposition to poor survival in cancer patients.
|
21412156 |
2011 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters.
|
16061909 |
2005 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggests that the FGFR4 Gly388Arg polymorphism most likely contributes to susceptibility to cancer, especially in Asians.
|
20638838 |
2010 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The rs351855 G>A polymorphism was associated with an increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41).
|
28445975 |
2017 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results suggest that FGFR4 rs351855G/A polymorphism is associated with increased susceptibility to NHL and could be used as a marker for predicting the prognosis of the malignancy.
|
24248544 |
2014 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.
|
23901234 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results provide evidence of a role for the FGFR4 Gly388Arg polymorphism in modulating patients' outcome in different types of cancer, thus offering to clinicians a new marker to predict predisposition to poor survival in cancer patients.
|
21412156 |
2011 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The rs351855 G>A polymorphism was associated with an increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41).
|
28445975 |
2017 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The FGFR4 Gly388Arg polymorphism is associated with cancer and cardiovascular diseases, but its association with hypertension is unclear.
|
28650667 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a wide variety of cancer types.
|
17519899 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results suggest that FGFR4 rs351855G/A polymorphism is associated with increased susceptibility to NHL and could be used as a marker for predicting the prognosis of the malignancy.
|
24248544 |
2014 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggests that the FGFR4 Gly388Arg polymorphism most likely contributes to susceptibility to cancer, especially in Asians.
|
20638838 |
2010 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.
|
23901234 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression.
|
26675719 |
2015 |